|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-9-5
|
|
pubmed:abstractText |
Optimal treatment for HIV-related visceral leishmaniasis (VL) has still to be established. A pilot clinical trial was carried out in 57 HIV-VL coinfected patients to compare the efficacy and safety of amphotericin B lipid complex (ABLC) versus meglumine antimoniate. The patients were randomized to receive either ABLC 3 mg/kg/day for 5 days (ABLC-5, 18 patients), ABLC 3 mg/kg/day for 10 days (ABLC-10, 20 patients) or meglumine antimoniate 20 mg Sbv /kg/day for 28 days (19 patients). Treatment was considered successful if parasites were not detected in a bone marrow aspirate after treatment. Parasitological cure was attained in 33% (95% CI: 13%-59%) of the ABLC-5 group, in 42% (95% CI: 16%-62%) of the ABLC-10 group and in 37% (95% CI: 16%-62%) of the meglumine antimoniate group (P = 0.94). Eight out of 19 patients administered antimoniate discontinued treatment prematurely following serious adverse events, compared with one in the ABLC groups (P = 0.0006). The efficacy of ABLC is similar to meglumine antimoniate, but the severity of toxicity in the treatment of HIV-VL is lower with ABLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0305-7453
|
|
pubmed:author |
pubmed-author:AlvarJorgeJ,
pubmed-author:ClotetBonaventuraB,
pubmed-author:Jiménez-MejíasManuel EME,
pubmed-author:López-VélezRogelioR,
pubmed-author:LagunaFernandoF,
pubmed-author:PradosDoloresD,
pubmed-author:RiberaEstebanE,
pubmed-author:SireraGuillemG,
pubmed-author:Spanish HIV-Leishmania Study Group,
pubmed-author:SustMarianoM,
pubmed-author:Torre-CisnerosJuliánJ,
pubmed-author:VidelaSebastiánS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
464-8
|
|
pubmed:dateRevised |
2008-9-25
|
|
pubmed:meshHeading |
pubmed-meshheading:12888588-Adult,
pubmed-meshheading:12888588-Amphotericin B,
pubmed-meshheading:12888588-Antiprotozoal Agents,
pubmed-meshheading:12888588-Bone Marrow,
pubmed-meshheading:12888588-Double-Blind Method,
pubmed-meshheading:12888588-Drug Combinations,
pubmed-meshheading:12888588-Female,
pubmed-meshheading:12888588-HIV Infections,
pubmed-meshheading:12888588-Humans,
pubmed-meshheading:12888588-Leishmaniasis, Visceral,
pubmed-meshheading:12888588-Male,
pubmed-meshheading:12888588-Meglumine,
pubmed-meshheading:12888588-Organometallic Compounds,
pubmed-meshheading:12888588-Phosphatidylcholines,
pubmed-meshheading:12888588-Phosphatidylglycerols,
pubmed-meshheading:12888588-Pilot Projects,
pubmed-meshheading:12888588-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
|
|
pubmed:affiliation |
Servicio de Enfermedades Infecciosas, Hospital Carlos III, Instituto de Salud Carlos III, C/Sinesio Delgado 12, 28029-Madrid, Spain. flaguna@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
